Explore Your Local Site

Looks like you've landed on our   site. Let's take you home:    

Please note that the content and products on the    site might not be available in your region.

 

Choose the language:

  Homepage
Continue on the current website:  

 

How to demonstrate Clinical Utility of AI and can this lead to further successful reimbursements?

How to demonstrate Clinical Utility of AI and can this lead to further successful reimbursements?

2024-03-27

Early diagnosis of a disease may affect treatment options and the patient’s ultimate prognosis. For many diseases, medical imaging...

Radiology
Academy

Medical Education
On Demand

Request a Meeting

How to demonstrate Clinical Utility of AI and can this lead to further successful reimbursements?

Video title from video component

YYMMDD Author/Uploaded by

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Tags

  • #Clinical utility

Duration

39m 6s

About this webinar

Early diagnosis of a disease may affect treatment options and the patient’s ultimate prognosis. For many diseases, medical imaging plays a critical function in diagnosis and assessment of therapeutic response. Most radiologists have encountered situations where a finding was missed that resulted in a delay of diagnosis or implementation of an inappropriate treatment plan. In some instances, the use of AI in certain clinical scenarios has been shown to improve patient outcomes and reduce hospital stays. AI for diagnostic Imaging has been around for more than 5 years but hasn’t yet been widely adopted. This may be caused by lack of real-world validation. Although the current pathways for reimbursement of digital diagnostics are not yet fully established, there is one universal truth when it comes to reimbursement in healthcare – clinical utility needs to be demonstrated. In today’s session, Franziska Lobig, Bayer Market Access Lead Radiology, will discuss how Bayer is leveraging their Pharmaceutical and Clinical Expertise to assess AI applications for their Calantic™ Marketplace. During the presentation, she will team up with Dr. Lauren Nicola, CEO Triad Radiology Associates and AI Reimbursement Thought Leader, in a live review on how to assess clinically relevant applications for reimbursement.

Speakers

References
  1. Cuocolo et al. Eur J Nuc Med Mol Imaging 2010
  2. Boellaard et al, 2015, Eur J Nucl Med Mol Imaging
  3. Antoch et al. JNM 2004
  4. Behrendt et al Eur Rad 2012
  5. Flavell et al. Acad Rad 2014